Levetiracetam Sciecure 100mg/ml concertrate solution for infusion

Strength

規(guī)格

500mg/5ml

Product   License

PL 43801/0042   - 0001

Indications

適應(yīng)癥

? on its own   in adults and adolescents from 16 years of age with newly   diagnosed epilepsy, to treat a certain form of epilepsy.

? partial   onset seizures with or without generalisation in adults, adolescents   and children from 4 years of age.

? myoclonic   seizures in adults and adolescents from 12 years of age with juvenile   myoclonic epilepsy.

? primary   generalised tonic-clonic seizures in adults and adolescents from 12 years of age with   idiopathic generalised epilepsy.

?在成人和16歲以下新診斷為癲癇的青少年中單獨(dú)治療某種形式的癲癇。

?成人、青少年和4歲以上兒童的部分發(fā)作性癲癇，伴有或不伴有全身性發(fā)作

?12歲以下患有青少年肌陣攣性癲癇的成人和青少年的肌陣攣性癲癇發(fā)作。

?12歲以下患有特發(fā)性全身性癲癇的成人和青少年的原發(fā)性全身強(qiáng)直陣攣發(fā)作。

Approved Date

批準(zhǔn)日期

15/02/2017

Market   Authorization Holder

持有人

SCIECURE   PHARMA LIMITED

Manufacture

生產(chǎn)商

Beijing   Sciecure Pharmaceutical Co., Ltd.

北京世橋生物制藥有限公司